GlassScriptPhysician profile
Kristen Buzzard
NPI 1972031961
$4,321.94
in general payments reported to CMS, 2019-2025
30 companies · $1,757 in 2025
The $1,757 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $193 · 2022: $689 · 2023: $699 · 2024: $984 · 2025: $1,757.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,431 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,431.06 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,100.47 | 2022-2025 | Vraylar, Qulipta |
| Pfizer INC. | $600.46 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $406.67 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $395.51 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $391.70 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Shield Therapeutics INC | $188.46 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $146.22 | 2021-2025 | Jardiance |
| Glaxosmithkline, LLC. | $107.45 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Dexcom, INC. | $104.38 | 2022-2023 | Dexcom G6 Transmitter |
| Abbott Laboratories | $92.28 | 2021-2025 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $91.47 | 2022-2025 | Xifaxan |
| Exact Sciences Corporation | $83.53 | 2024-2025 | Cologuard Collection Kit |
| Amgen INC. | $74.08 | 2022-2025 | Repatha, Otezla, Otezla |
| Merck Sharp & Dohme LLC | $68.58 | 2021-2024 | Gardasil, Gardasil 9, Capvaxive |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $66.84 | 2025 | Caplyta |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $46.09 | 2024-2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $45.67 | 2021-2025 | |
| Ultragenyx Pharmaceutical INC. | $35.08 | 2022 | |
| Spr Therapeutics, INC | $33.68 | 2025 | Sprint Pns System |
| Mannkind Corporation | $30.97 | 2025 | |
| Sanofi-Aventis U.S. LLC | $30.58 | 2022 | |
| Organon LLC | $29.09 | 2022-2025 | Nexplanon |
| Otsuka America Pharmaceutical, INC. | $26.63 | 2025 | Rexulti |
| Astellas Pharma US INC | $21.26 | 2024 | Veozah |
| Amarin Pharma, INC. | $21.08 | 2022 | |
| Axsome Therapeutics, INC. | $20.32 | 2025 | Symbravo |
| Sunovion Pharmaceuticals INC. | $19.12 | 2022 | |
| Idorsia Pharmaceuticals US INC | $15.97 | 2023 | Quviviq |
| Takeda Pharmaceuticals U.S.A., INC. | $14.82 | 2021 | |
| Sumitomo Pharma America, INC. | $13.48 | 2025 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristen Buzzard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.